Intranasal fluticasone furoate in pediatric allergic rhinitis: randomized controlled study

Area of Science:

• Pediatric Allergy and Immunology
• Pharmacology and Therapeutics
• Clinical Research

Background:

• Allergic rhinitis (AR) is prevalent in children.
• Intranasal corticosteroids are effective AR treatments.
• Limited data exist on intranasal corticosteroid efficacy and safety in Chinese pediatric populations.

Purpose of the Study:

• To evaluate the efficacy and safety of fluticasone furoate nasal spray (FFNS) in Chinese children with AR.
• To assess FFNS in a pediatric population aged 2-12 years.
• To provide data on FFNS for younger children (2-6 years).

Main Methods:

• Phase 4, randomized, double-blind, placebo-controlled, multicenter study.
• Pediatric AR patients (2-12 years) received FFNS (55 µg or 110 µg) or placebo.
• Symptoms, rescue medication use, and safety were monitored via electronic diaries and clinical assessments.

Main Results:

• FFNS significantly reduced total nasal symptom scores compared to placebo in all patients.
• Efficacy was consistent in younger children (2-6 years).
• Adverse events were infrequent (<20%) and FFNS was well tolerated.

Conclusions:

• FFNS (55 µg and 110 µg) shows favorable efficacy and safety in Chinese pediatric AR patients (2-12 years).
• FFNS is suitable for treating AR in children, including those aged 2-6 years.
• The findings support FFNS use in clinical practice for pediatric AR.